Considering that we now have RNA-interference silencing and RNA antisense oligonucleotide drugs for treatment of hATTR neuropathy (9), as well as TTR tetramer stabilizer treatment for TTR cardiomyopathy (10), it is even more relevant than before, to determine what clinical factors should be used to efficiently identify hATTR before it progresses to advanced disease. The gene discussed is TTR; the disease is cardiomyopathy.